Taiwan FDA registration e3d3617905d5c93f0166c8767811e87f
Primmus PDQ Plus fully automated glycoglobin analysis system
TW: 普林莫斯PDQ Plus全自動化醣化血色素分析系統
Taiwan·Risk Class 2·TRINITY BIOTECH PRIMUS CORPORATION DBA TRINITY BIOTECH·Registered Feb 16, 2006 – Feb 16, 2021CancelledRegistration details
- Analysis ID
- e3d3617905d5c93f0166c8767811e87f
- Customs Code
- DHA00601600200
Company information
- Manufacturer Country
- United States
- Authorized Representative
- PROGRESSIVE GROUP INC.
Product details
- Intended Use
- High-pressure liquid chromatography was used as an in vitro diagnostic to quantify glycoglobin.
- Product Type (Level 1)
- B Hematology, pathology, and genetics
- Product Type (Level 2)
- B.7470 Analysis of glycosylated hemoglobin
- Import Information
- import
Dates and status
- Registration Date
- Feb 16, 2006
- Expiry Date
- Feb 16, 2021
- Cancellation Date
- Sep 19, 2023
Cancellation information
- Status
- Logged out
- Reason
- 自行鍵入
About this record
Access comprehensive regulatory information for Primmus PDQ Plus fully automated glycoglobin analysis system in Taiwan's medical device market through Pure Global AI's free database. This Risk Class 2 medical device is registered under number e3d3617905d5c93f0166c8767811e87f and manufactured by TRINITY BIOTECH PRIMUS CORPORATION DBA TRINITY BIOTECH. The authorized representative in Taiwan is PROGRESSIVE GROUP INC..
This page provides complete technical specifications, regulatory compliance details. Pure Global AI offers free access to 89,000+ Taiwan medical device registrations, helping global MedTech companies navigate Taiwan FDA regulations, identify competitors, and discover partnership opportunities efficiently.
Free DatabasePowered by Pure Global AI89,000+ Devices